"We do not seek conflict with Iran or any other country," Trump tells reporters in the Oval Office.Politicsread more
While earnings usually come in substantially ahead of expectations — as much as 4 or 5 percentage points is not unusual — the downward direction in the outlook doesn't speak...Earningsread more
Goldman Sachs says there's still life left in value investing, especially with the Federal Reserve set to cut rates again.Marketsread more
Shopify debuts a new network to help it compete with Amazon.Marketsread more
"We missed being the dominant mobile operating system by a very tiny amount. We were distracted during our antitrust trial. We didn't assign the best people to do the work,"...Technologyread more
Sen. Bernie Sanders announced a plan Monday to forgive the country's $1.6 trillion outstanding student loan tab, intensifying the higher education policy debate in the 2020...Personal Financeread more
Some traders think the energy rally is about to wane, despite the sector being one of June's big winners.ETF Edgeread more
The world's most innovative district will include less of Google.Technologyread more
Stocks with this one feature are poised to crush the market after a rate cut, according to Goldman Sachs.Marketsread more
Nineteen billionaires release a letter asking the 2020 presidential candidates to support a tax on America's richest families.Economyread more
Apple has released the iOS 13 public beta and the iPadOS public preview, which means you can check out the features before it launches this fall.Technologyread more
Shares in Bayer plunged more than 10 percent to their lowest in almost two years after a California jury ordered the German company's subsidiary Monsanto to pay $289 million in damages last week.
A jury found Monsanto liable in a lawsuit alleging that the company's glyphosate-based weedkillers, including its Roundup brand, caused cancer. The case against Monsanto, which Bayer acquired this year for $63 billion, is the first of more than 5,000 similar lawsuits across the United States.
Monsanto said on Friday that it would appeal against the verdict.
"Today's decision does not change the fact that more than 800 scientific studies and reviews ... support the fact that glyphosate does not cause cancer," it said in a statement.
Bayer shares were down 10.6 percent at 83.48 euros at 0728 GMT, against a 0.6 decline for the DAX index.
In Europe the EU Commission in December renewed the licence for glyphosate despite intense debate over its safety, though Germany and France have taken steps to phase out use of the weedkiller.
Originally an exclusive Monsanto brand, patent-free glyphosate herbicides are now sold by the global crop-protection industry